

## CLAIMS

1. An antibody or antigen-binding fragment thereof, comprising
  - (a) a heavy chain variable region (VH) comprising a CDR-H1, CDR-H2, and CDR-H3 encoded by the nucleic acid of SEQ ID NO:47; and
  - (b) a light chain variable region (VL) comprising a CDR-L1, CDR-L2, and CDR-L3 encoded by the nucleic acid of SEQ ID NO:51.
2. The antibody or antigen-binding fragment thereof of claim 1, wherein
  - (a) the VH comprises
    - (i) a CDR-H1 comprising the amino acid sequence of GFKFDDYAM (SEQ ID NO:13);
    - (ii) a CDR-H2 comprising the amino acid sequence of LNWNGDITA (SEQ ID NO:7);
    - (iii) a CDR-H3 comprising the amino acid sequence of SWGDYTRGPEPKITWY (SEQ ID NO:14); and
  - (b) the VL comprises
    - (i) a CDR-L1 comprising the amino acid sequence of GIDGYL (SEQ ID NO:15);
    - (ii) a CDR-L2 comprising the amino acid sequence of SLL (SEQ ID NO:9); and
    - (iii) a CDR-L3 comprising the amino acid sequence of LDSYPLFTF.
3. The antibody or antigen-binding fragment thereof of claim 1, wherein
  - (a) the VH comprises the amino acid sequence of  
EVQLVESGGRALRPGGSLRLSCAASGFKFDDYAMSWVRQVPGKGLEFVS  
GLNWNGDITAYTDSVKGRETVSRDNAKNSLYLHINSPKPEDTALYYCAR  
TSSWGDYTRGPEPKITWYFDLWGRGTLVTVSS (SEQ ID NO:44); and
  - (b) the VL comprises the amino acid sequence of  
DIQLTQSPSFLSASVGDRITITCRASQGIDGYLAWYQQRPGKAPNLLIYAA  
SLLQSGVPSRFSGSGYGTEFTLTISLQPEDFATYYCQHLDSYPLFTFGPGT  
KVDIK.
4. The antibody or antigen-binding fragment thereof of any one of claims 1-3, further comprising an amino acid sequence of an antibody hinge and/or constant region.

5. The antibody or antigen-binding fragment thereof of claim 4, wherein the constant region is a human or humanized constant region.
6. The antibody or antigen-binding fragment of any one of claims 1-3, wherein the antibody or antigen-binding fragment inhibits the neuraminidase with an IC<sub>50</sub> of 0.0001 µg/ml to 30 µg/ml.
7. The antibody or antigen-binding fragment of any one of claims 1-3, for use in preventing or treating influenza infection in a subject in need thereof.
8. The antibody or antigen-binding fragment for use according to claim 7, wherein the influenza infection is caused by an influenza A virus or an influenza B virus.
9. A pharmaceutical composition comprising the antibody or antigen-binding fragment of any one of claims 1-3, and a pharmaceutically acceptable carrier or excipient.
10. The pharmaceutical composition of claim 9, for use in preventing or treating influenza infection in a subject in need thereof.
11. The pharmaceutical composition for use according to claim 10, wherein the influenza infection is caused by an influenza A virus or an influenza B virus.
12. A nucleic acid, comprising the nucleic acid sequence of SEQ ID NO:47 and/or SEQ ID NO:51.
13. The nucleic acid of claim 12, further comprising a nucleic acid sequence encoding an antibody hinge and/or constant region.
14. The nucleic acid of claim 14, wherein the constant region is a human or humanized constant region.
15. An expression vector, comprising the of any one of claims 12-14.
16. A host cell, comprising the expression vector of claim 15.
17. A method of producing an antibody or antigen-binding fragment thereof, comprising culturing the host cell of claim 16 to express the antibody or antigen-binding fragment thereof.

18. The method of claim 17, further comprising isolating the antibody or antigen-binding fragment thereof.